VTGN Stock Overview
A biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Vistagen Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.93 |
| 52 Week High | US$5.74 |
| 52 Week Low | US$2.22 |
| Beta | 0.77 |
| 1 Month Change | -1.35% |
| 3 Month Change | 13.57% |
| 1 Year Change | -40.69% |
| 3 Year Change | -93.02% |
| 5 Year Change | -80.94% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely
Nov 15
VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis
Sep 08VistaGen drops 80% as late-stage study for anxiety therapy fails
Jul 22Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation
Apr 10VistaGen Therapeutics added to Russell 2000 Index
Jun 16VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business
Jun 07VistaGen initiates late-stage trial of PH94B in social anxiety disorder
May 26VistaGen names new chief commercial officer
May 04How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?
Feb 16
Shareholder Returns
| VTGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.3% | 2.2% | -2.2% |
| 1Y | -40.7% | -1.9% | 18.3% |
Return vs Industry: VTGN underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: VTGN underperformed the US Market which returned 18.3% over the past year.
Price Volatility
| VTGN volatility | |
|---|---|
| VTGN Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VTGN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VTGN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 48 | Shawn Singh | www.vistagen.com |
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women’s health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders.
Vistagen Therapeutics, Inc. Fundamentals Summary
| VTGN fundamental statistics | |
|---|---|
| Market cap | US$84.57m |
| Earnings (TTM) | -US$47.30m |
| Revenue (TTM) | US$698.00k |
121.2x
P/S Ratio-1.8x
P/E RatioIs VTGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTGN income statement (TTM) | |
|---|---|
| Revenue | US$698.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$698.00k |
| Other Expenses | US$48.00m |
| Earnings | -US$47.30m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.64 |
| Gross Margin | 100.00% |
| Net Profit Margin | -6,777.08% |
| Debt/Equity Ratio | 0% |
How did VTGN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 06:03 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vistagen Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Lin Tsai | Jefferies LLC |
| Jason McCarthy | Maxim Group |